Compare

Novozymes A/S/DKr NSIS B

1D1W1M3M6MYTD1Y5YMAX

About Novozymes A/S

Novozymes A/S is a biotechnology company headquartered in Bagsværd, Denmark, specializing in the production and distribution of enzymes and microbial solutions. The company's core business spans multiple industries, including agriculture, bioenergy, food and beverages, and household care. Novozymes develops essential products such as enzymes for laundry detergents, animal feed additives, and biofuel production aids. Founded in 2000, it originated from a division of the pharmaceutical company Novo Nordisk. The company has a global presence, with significant operations in North America, Europe, and Asia. Novozymes is strategically positioned to capitalize on growing demand for sustainable solutions through its strong commitment to innovation and extensive expertise in biosolutions.
Ticker
DKr NSIS B
Sector
Materials
Primary listing
CSE
Employees
11,098
Headquarters
Lyngby, Denmark
Website
www.novonesis.com

Novozymes A/S Metrics

BasicAdvanced
kr 217B
46.01
kr 10.12
0.62
kr 6.60
1.42%

Bulls say / Bears say

Novonesis grew organic sales by 8% in the first half of 2026 and raised its full-year growth outlook to 7–8%, with the adjusted EBITDA margin expected at the top end of its 37–38% range. This points to strong near-term trading and profit resilience. (Novonesis)
Revenue synergies contributed about one percentage point to first-half sales growth, and management says the Feed Enzyme Alliance acquisition is delivering in line with its commitments. These are signs that the broader combined offering is translating into commercial gains. (Novonesis)
The completed MicroBioGen acquisition adds specialist yeast-breeding expertise with a proven bioethanol track record. Novonesis sees potential to apply that technology in other industries, giving it another route to develop biosolutions and future sales. (Novonesis)
Human Health is expected to grow only slightly in 2026, as the US dietary-supplements market remains cautious. That leaves a part of the business with limited near-term growth. (Novonesis)
Agriculture, Energy & Tech grew 7% in the first half, below the 8.6% analysts expected, and its Plant business remained weak. The segment’s uneven performance and an expected reversal of animal-customer inventory build-up could make growth less dependable. (Inderes)
Net financial expenses nearly doubled year on year to €29.9 million, according to Inderes, as the €1.7 billion bond issuance to refinance the acquisition facility flowed through. Higher financing costs can dilute the benefit of operating growth for shareholders. (Inderes, Inderes)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.

Funds containing Novozymes A/S

AllEURUSD
Funds
Fund name
Fund size
DKr NSIS B weighting
Xtrackers MSCI Nordic£XDN0
€1.1B1.64%
iShares STOXX Europe 600 Health Care€EXV4
€709M1.23%
SPDR MSCI World Materials€WMAT
$206M0.86%
iShares MSCI Europe SRI€IESE
€3.2B0.72%
iShares MSCI Europe SRI£IESG
€3.2B0.72%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.